RxDoctor Payments Data

Jon Heist, DO

Family Medicine · Glassboro, NJNPI 1760501373

Payments from drug & device makers

$6,211in general payments, 2019–2025

Across 443 payments — averaging $14.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$833
  • GSK$806
  • Novo Nordisk$520
  • AstraZeneca$508
  • Amarin Pharma, Inc.$287
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$6,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,211 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$86,556
Medicare patients
195
Services billed
1,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$38,964
EliquisApixaban22$37,037
FarxigaDapagliflozin Propanediol20$28,427
MounjaroTirzepatide15$23,510
XareltoRivaroxaban16$16,978
Pitavastatin Calcium12$4,530
Rosuvastatin Calcium256$4,063
Metoprolol Succinate134$3,191
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine101$3,047
Propranolol Hcl ErPropranolol Hcl35$2,991
Amlodipine Besylate365$2,906
Pravastatin Sodium162$2,904
Atorvastatin Calcium218$2,757
Pantoprazole Sodium132$2,527
Levothyroxine Sodium269$2,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$520$38,96426 claims
PfizerEliquis$193$37,03722 claims
AstraZenecaFarxiga$508$28,42720 claims
Lilly USA, LLCMounjaro$200$23,51015 claims
Johnson & JohnsonXarelto$26$16,97816 claims
AbbVieSynthroid$1,339$2,38322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Glassboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →